Annal Meleth
Ophthalmology · Marietta, GANPI 1962668046
Payments from drug & device makers
Across 434 payments — averaging $1027.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$134K
- Regeneron$133K
- Roche TCRC, Inc.$67K
- Eyepoint US, Inc.$61K
- Bayer$30K
- AbbVie$6K
- plus $16K from 27 others
Across 8 payments — averaging $221.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$16,11548%
- Speaking & faculty fees$7,48522%
- Travel & lodging$1,4214%
- Food & beverage$8,67426%
- Entertainment$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 51 | $133,680 |
| Regeneron | 56 | $132,691 |
| Roche TCRC, Inc. | 8 | $67,174 |
| Eyepoint US, Inc. | 26 | $60,620 |
| Bayer | 11 | $29,587 |
| AbbVie(2 entities) | 27 | $6,314 |
| Alimera Sciences, Inc. | 20 | $5,925 |
| Novartis | 23 | $3,860 |
| Genentech USA, Inc. | 49 | $1,210 |
| Astellas Pharma US Inc | 25 | $899 |
| Regeneron Healthcare Solutions, Inc. | 37 | $898 |
| Mallinckrodt Hospital Products Inc. | 24 | $716 |
| Apellis Pharmaceuticals, Inc. | 14 | $538 |
| Alcon | 6 | $274 |
| Bausch & Lomb Americas Inc. | 11 | $241 |
| ANI Pharmaceuticals, Inc. | 10 | $195 |
| Carl Zeiss Meditec USA, Inc. | 1 | $128 |
| Sandoz | 4 | $124 |
| Sun Pharmaceutical Industries Inc. | 3 | $112 |
| Mallinckrodt Enterprises LLC | 4 | $83 |
| Coherus Oncology, Inc. | 5 | $81 |
| Glaukos Corporation | 1 | $61 |
| Harrow Eye, LLC | 2 | $60 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $52 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Optos, Inc. | 1 | $26 |
| Shire North American Group Inc | 1 | $22 |
| NEW World Medical,inc. | 1 | $20 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Maculogix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$445,757 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $10,969 |
| Difluprednate | 97 | $10,831 |
| ProlensaBromfenac Sodium | 28 | $10,785 |
| Prednisolone Acetate | 146 | $9,033 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $7,848 |
| Cyclosporine | 14 | $6,165 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,689 |
| Bromfenac Sodium | 15 | $3,500 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 138 | $2,451 |
| Ketorolac Tromethamine | 47 | $1,809 |
| Latanoprost | 104 | $1,376 |
| MoxifloxacinMoxifloxacin Hcl | 62 | $1,302 |
| ValacyclovirValacyclovir Hcl | 15 | $1,288 |
| Brimonidine Tartrate | 48 | $1,188 |
| Atropine Sulfate | 16 | $1,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $6,314 | $18,81840 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $48 | $10,78528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Marietta
- Robert StoltzMarietta$3.9M
- Lakshmana KooragayalaMarietta$1.4M
- Puneet PandaMarietta$185K
- Rajesh RangarajMarietta$23K
- Dennis MarcusAugusta$9.2M
- Eugene McLaurinSavannah$3.3M
- Clayton BlehmGainesville$1.7M
- Douglas DayAtlanta$1.1M
- Jennifer KimMorrow$989K
- Thomas AabergAtlanta$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.